1Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA; 2Department of Medicine, University of Washington, Seattle; 3Department of Pediatric Hematology-Oncology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA; 4Department of Laboratory Medicine, University of Washington, Seattle; and 5Department of Radioimmunotherapy and 6Division...

Many different radiolabeled antibodies have been used for radioimmunotherapy and radioimmunoscintigraphy of human diseases in animal experiments. In order to study the in vivo tissue distribution of antibody, we labeled human nonspecific polyclonal IgG with Na125I using chloramine-T method. An animal model was developed by injecting turpentine in the posterior left thigh of Balb/c mice. Tissue ...

Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radioimmunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic ...

We have previously shown that, monoclonal antibodies (mAbs) labeled with the Auger electron emitter I are more in vitro, 125 cytotoxic if they remain at the cell surface and do not internalize in the cytoplasm. Here, we assessed the biological efficiency in vivo of internalizing and non internalizing I-labeled mAbs for the treatment of small solid tumors. 125

Radioimmunotherapy (RIT or RAIT) dates back more than 2 decades and has evolved to encompass a variety of tumorseeking antibodies in various forms, with different radionuclides, different delivery methods, for different clinical indications (usually advanced disease).1 Although selective antibody targeting has been demonstrated, the radiation doses delivered have been insufficient to markedly i...

PURPOSE This study examined a pretarget radioimmunotherapy strategy for treatment of an i.p. tumor model (LS174T). EXPERIMENTAL DESIGN The strategy used regional administration (i.p.) of a novel targeting molecule composed of four CC49 anti-tumor-associated glycoprotein 72 (TAG-72) single-chain antibodies linked to streptavidin as a fusion protein (CC49 fusion protein); 24 hours later, a synt...

Introduction The optimistic and naive view of the early l980s that mAbs2 were ‘ ‘ magic bullets’ ‘ has now been replaced by a more realistic understanding of the many obstacles to their effective use. Although some mAbs have produced significant antitumor responses in humans (1-6), a number of factors, including the weak cytotoxic activity of many murine mAbs. the difficulty in delivering mAbs ...

Streptococcus pneumoniae is an important cause of community-acquired pneumonia, meningitis, and bacteremia. The problem of pneumococcal disease is exacerbated by increasing drug resistance. Furthermore, patients with impaired immunity are at high risk for invasive pneumococcal infections. Thus, there is an urgent need for new approaches to antimicrobial therapy. Antibody therapies take advantag...

PURPOSE To evaluate the differences in the outcomes of patients with stage II and IIIa non-small cell lung cancer (NSCLC) treated with either 131I-labeled mouse/human chimeric monoclonal antibody against intracellular DNA exposed in necrotic and degenerating regions of tumors (131I-chTNT-mediated radioimmunotherapy) combined with percutaneous microwave coagulation therapy (PMCT) guided by compu...

Radioimmunotherapy is a highly effective treatment for some hematologic malignancies; however, the underlying mechanisms of tumor clearance remain poorly understood. We have previously shown that both targeted radiation using (131)I-labeled anti-MHC class II (MHCII) monoclonal antibody (mAb) plus mAb signaling with unlabeled anti-idiotype are required for the long-term clearance of tumor in syn...